RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+7.19%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$811M
AUM Growth
+$71.2M
(+9.6%)
Cap. Flow
+$37.6M
Cap. Flow
% of AUM
4.63%
Top 10 Holdings %
Top 10 Hldgs %
28.89%
Holding
102
New
7
Increased
37
Reduced
34
Closed
10
Top Buys
| 1 |
Becton Dickinson
BDX
|
$16.3M |
| 2 |
CVS Health
CVS
|
$15.8M |
| 3 |
Bristol-Myers Squibb
BMY
|
$13.9M |
| 4 |
CELG
Celgene Corp
CELG
|
$12M |
| 5 |
Cigna
CI
|
$10.9M |
Top Sells
| 1 |
Nektar Therapeutics
NKTR
|
$15.5M |
| 2 |
ADMS
Adamas Pharmaceuticals, Inc.
ADMS
|
$11.5M |
| 3 |
Esperion Therapeutics
ESPR
|
$10.3M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$6.14M |
| 5 |
Cencora
COR
|
$6.03M |
Sector Composition
| 1 | Healthcare | 94.68% |
| 2 | Technology | 0.23% |
| 3 | Energy | 0.22% |
| 4 | Financials | 0.18% |
| 5 | Consumer Discretionary | 0.06% |